October 24, 2025

Age-stratified risk factors and predictive models for progression to lupus nephritis in patients with systemic lupus erythematosus: a review – Frontiers

October 23, 2025

After Setbacks, FDA Approves Belantamab Mafodotin Combo in Myeloma – Targeted Oncology

October 23, 2025

Entering the era of precision medicine to treat amyotrophic lateral sclerosis – Molecular Neurodegeneration

October 23, 2025

Blenrep Approved: What This Means for the Myeloma Community

The MMRF is excited to share that the FDA has approved Blenrep (belantamab mafodotin) combinations for multiple myeloma patients who have relapsed and have received at least two prior lines of treatment. The announcement was eagerly anticipated, especially after the FDA took some time to weigh the data presented at July’s Oncology Drug Advisory Committee […]

October 23, 2025

Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets – Nature